The effect of intravenous-to-oral switch guidelines on the use of parenteral antimicrobials in medical wards

被引:51
作者
Laing, RBS [1 ]
Mackenzie, AR
Shaw, H
Gould, IM
Douglas, JG
机构
[1] Aberdeen Royal Infirm, Infect Unit, Aberdeen AB25 2ZB, Scotland
[2] Aberdeen Royal Infirm, Dept Pharm, Aberdeen AB25 2ZB, Scotland
[3] Univ Aberdeen, Dept Med Microbiol, Aberdeen, Scotland
关键词
D O I
10.1093/jac/42.1.107
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The effect of an intravenous (iv)-to-oral switch policy on antibiotic prescribing in general medical wards was examined. Three audits, each of 2 months' duration, were carried out to examine the duration of iv therapy and length of patient stay. The first audit (S1) was performed before the introduction of switch guidelines, the second (S2) after guidelines had been placed in patient case-notes and the third (S3) after the guidelines had been introduced into the drug charts. The duration of iv therapy was significantly shorter in the S3 group (mean = 3.7 days) than in the S2 or S1 groups (mean 4.4 and 4.35 days, respectively) (P < 0.05). There was no significant difference in the length of patient stay between the three audit periods but the stay was significantly shorter in 81 switched patients (mean duration = 8.9 days) than in matched controls (mean duration = 12.6 days) (P = 0.01). Fewer patients with respiratory infection were treated for >24 h with iv antimicrobials in the S3 audit period (75/549) than in the S2 (85/372) and S1 audits (83/326) (P < 0.01). The introduction of switch guidelines to drug charts reduces the length of iv therapy. Switched patients spend less time in hospital than their matched controls.
引用
收藏
页码:107 / 111
页数:5
相关论文
共 9 条
[1]  
Allen Barbara, 1992, Australian Journal of Hospital Pharmacy, V22, P434
[2]  
BROOKS M, 1995, IRISH PHARM J, P225
[3]   SERUM LEVELS OF CIPROFLOXACIN AFTER SINGLE ORAL DOSES IN PATIENTS WITH SEPTICEMIA [J].
DESPINE, M ;
BELLIDO, F ;
PECHERE, JC ;
AUCKENTHALER, R ;
ROHNER, P ;
LEW, D ;
HIRSCHEL, B .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1989, 8 (12) :1019-1023
[4]   INTRAVENOUS-TO-ORAL STEPDOWN PROGRAM - 4 YEARS OF EXPERIENCE IN A LARGE TEACHING HOSPITAL [J].
FRIGHETTO, L ;
NICKOLOFF, D ;
MARTINUSEN, SM ;
MAMDANI, FS ;
JEWESSON, PJ .
ANNALS OF PHARMACOTHERAPY, 1992, 26 (11) :1447-1451
[5]   CLINICAL AND ECONOMIC-IMPACT OF ORAL CIPROFLOXACIN AS FOLLOW-UP TO PARENTERAL ANTIBIOTICS [J].
GRASELA, TH ;
PALADINO, JA ;
SCHENTAG, JJ ;
HUEPENBECKER, D ;
RYBACKI, J ;
PURCELL, JB ;
FIEDLER, JB .
DICP-THE ANNALS OF PHARMACOTHERAPY, 1991, 25 (7-8) :857-862
[6]  
Hamilton-Miller J. M. T., 1996, Clin Microbiol Infect, V2, P12, DOI 10.1111/j.1469-0691.1996.tb00194.x
[7]   Sequential antimicrobial therapy - the role of quinolones [J].
Nathwani, D ;
Tillotson, G ;
Davey, P .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (04) :441-446
[8]  
QUINTILIANI R, 1991, REV INFECT DIS S9, V13, P770
[9]   ADVANCES IN ANTIBIOTIC USE - SWITCH THERAPY [J].
RAMIREZ, JA .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1994, 55 :30-34